← Back to All US Stocks

BGM Stock Analysis - BGM Group Ltd. AI Rating

BGM Nasdaq Pharmaceutical Preparations E9 CIK: 0001779578
Recently Updated • Analysis: Mar 20, 2026 • SEC Data: 2026-03-20
AI Rating
HOLD
5% Confidence

📊 BGM Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 5% confidence

Investment Thesis

BGM Group Ltd. presents an unanalyzable investment case due to complete absence of SEC financial data. No revenue, profitability, balance sheet, or cash flow metrics are available, making fundamental analysis impossible. Without financial disclosure, investor risk cannot be assessed.

BGM Strengths

  • + Listed on Nasdaq, suggesting minimum regulatory compliance requirements met
  • + Pharmaceutical sector has potential for high-margin products
  • + Theoretically positioned in healthcare industry with structural growth trends

BGM Risks

  • ! No financial data available - inability to assess solvency or operational performance
  • ! Zero insider activity in last 90 days - potential lack of management confidence or engagement
  • ! Appears to be non-reporting or shell company status - severe transparency and information risk

Key Metrics to Watch

BGM Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

BGM Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

BGM vs Healthcare Sector

How BGM Group Ltd. compares to Healthcare sector averages

Net Margin
BGM 0.0%
vs
Sector Avg 12.0%
BGM Sector
ROE
BGM 0.0%
vs
Sector Avg 15.0%
BGM Sector
Current Ratio
BGM 0.0x
vs
Sector Avg 2.0x
BGM Sector
Debt/Equity
BGM 0.0x
vs
Sector Avg 0.6x
BGM Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

BGM Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

BGM Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

BGM SEC Filings

Access official SEC EDGAR filings for BGM Group Ltd. (CIK: 0001779578)

📋 Recent SEC Filings

Date Form Document Action
Dec 3, 2024 SC 13D tm2429887d1_sc13d.htm View →
Oct 16, 2024 SC 13D tm2425844d1_sc13d.htm View →
Feb 10, 2021 SC 13G tm216142d3_sc13g.htm View →
Feb 10, 2021 SC 13G tm216142d2_sc13g.htm View →
Feb 10, 2021 SC 13G tm216142d1_sc13g.htm View →

Frequently Asked Questions about BGM

What is the AI rating for BGM?

BGM Group Ltd. (BGM) has an AI rating of HOLD with 5% confidence, based on fundamental analysis of SEC EDGAR filings.

What are BGM's key strengths?

Listed on Nasdaq, suggesting minimum regulatory compliance requirements met. Pharmaceutical sector has potential for high-margin products.

What are the risks of investing in BGM?

No financial data available - inability to assess solvency or operational performance. Zero insider activity in last 90 days - potential lack of management confidence or engagement.

What is BGM's revenue and growth?

BGM Group Ltd. reported revenue of N/A.

Does BGM pay dividends?

BGM Group Ltd. does not currently pay dividends.

Where can I find BGM SEC filings?

Official SEC filings for BGM Group Ltd. (CIK: 0001779578) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is BGM's EPS?

BGM Group Ltd. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 20, 2026 | Data as of: 2026-03-20 | Powered by Claude AI